医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

The IV2 Alliance, Inc. and Telangana, India Establish Pathway to Advance Global Health

2016年10月19日 AM03:20
このエントリーをはてなブックマークに追加


 

WHITE OAK, Md.

Representatives from The IV2 Alliance, Inc., a Maryland non-profit corporation, and the government of the State of Telangana, India, have signed a Memorandum of Understanding (MOU) to establish the framework for the two entities to explore collaborative opportunities that will advance regulatory science and drive biomedical innovation, in conjunction with The IV2’s MOU (US FDA MOU Control Number 225-12-0025) with the U.S. Food and Drug Administration (U.S. FDA).

“The recent, historic signing ceremony occurring near the U.S. FDA headquarters in Montgomery County, Maryland, establishes the pathway to further build upon the International Sister Cities agreement signed by Montgomery County, Md. and the City of Hyderabad, Telangana in September of 2014 to create cooperation between the jurisdictions,” said Mr. Jonathan M. Genn, Esq., President of The IV2 Alliance, Inc. and Executive Vice President and General Counsel, Global LifeSci Development Corporation.

The MOU ensures the entities will engage in the joint promotion of economic development, science/technology, commercial, and financial activities within Montgomery County, Maryland and Hyderabad, Telangana, India, with emphasis on the planned VIVA White Oak™ mixed-use biomedical cluster in Montgomery County, and the planned Hyderabad Pharma City in Hyderabad, Telangana, India.

Kalvakuntla Taraka Rama Rao, Cabinet Minister for the Government of Telangana, India projects, “Telangana is becoming the most exciting investment destination in India.”

The Global LifeSci Development Corporation (GLDC), an affiliate of The IV2, has entered into a public-private partnership with Montgomery County, Md. to develop the international epicenter for advancing global health and biomedical innovations known as “VIVA White Oak™.”

“With the consolidation of the U.S. FDA Headquarters, the expansion of Washington Adventist Hospital, and the planned 300-acre VIVA White Oak™ mixed-use community with a biomedical and biotechnological emphasis, White Oak has a unique opportunity to create one of the world’s most significant biomedical clusters,” said County Executive Isiah Leggett.

Arvind Kumar, Telangana Principal Secretary for Industries and Commerce and Genn signed the agreement. Other supporting participants at the ceremony included Minister Rao; County Executive Leggett; Dr. Frank Weichold, U.S. FDA Director, Science and Innovation, OCS, OC; Nancy Floreen, Montgomery County Council President; and Judy Costello, Director of the Office of BioHealth and Life Sciences for the Maryland Department of Commerce.

About IV2 Alliance, Inc.

The IV2 Alliance, Inc. is a Maryland non-profit corporation to promote collaboration within the scientific, research and provider communities to achieve advances in the field of Regulatory Science, Biomedical Innovation and the promotion of global health. The IV2 is planned to be constituted by a consortium of sixteen (16) preeminent international academic, research and clinical universities and institutions, working in collaboration with patient advocacy groups, private sector enterprises within the industry, international partners, and other stakeholders.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161018006570/en/

CONTACT

The IV2 Alliance, Inc.
Media Contact:
Laura
Van Eperen, 1-240-994-7541
laura@vaneperen.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Groundbreaking Multi-Center Clinical Trial Confirms Low-Dose Aspirin Therapy Reduces Rate of Pre-Term Preeclampsia
  • 武田薬品、初発多発性骨髄腫患者および維持療法でニンラーロ(イキサゾミブ)を検討する第1/2相試験のデータを発表
  • LEDを自然な光に回帰させるソウル半導体の新技術“SunLike”
  • 武田呈报NINLARO™ (ixazomib)用于新诊断多发性骨髓瘤患者及维持治疗的1/2期研究数据
  • Eloxx Pharmaceuticals Receives a US$6 Million Investment from KIP and DCS to Advance a Novel Disease-Modifying Therapy Targeting Genetic Diseases Including Cystic Fibrosis